SAN DIEGO – RemeGen Co., a Chinese biopharmaceutical firm, is showcasing promising Phase III clinical trial results for its novel drug, Telitacicept (RC18), at the ACR Convergence 2023 in San Diego Convention Center today. The drug is designed to combat immunological diseases by preventing abnormal B cell differentiation and has…Read More
RemeGen reveals positive Phase III results for RA drug at ACR Convergence By Investingcom
